document id	subject	predicate	predicate lemmatized	object	confidence	sentence
30160001	a heterogeneous group of carcinomas	 has advanced	  have advance	in recent years	0.94	Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .
30160001	Tumors in the neck region	 include	  include	a heterogeneous group of carcinomas whose treatment has advanced in recent years	0.58	Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .
30160001	Tumors in the head region	 include	  include	a heterogeneous group of carcinomas whose treatment has advanced in recent years	0.45	Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .
30160002	Tumors in the neck region	 comprise	  comprise	a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years	0.66	Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .
30160002	Tumors in the head region	 comprise	  comprise	a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years	0.53	Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .
30160002	carcinomas progress	 has been observed	  have be observe	in recent years	0.23	Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .
30160002	heterogeneous group carcinomas therapy progress	 has been observed	  have be observe	in recent years	0.18	Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .
30160021	those	 affected	  affect		0.92	This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected .
30160021	This shift	 changes	  change	the understanding of the disease	0.40	This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected .
30160021	This shift	 changes	  change	the life expectancy of those	0.39	This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected .
30160021	This shift	 changes	  change	its therapy	0.04	This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected .
30160022	those	 affected	  affect		0.92	This changes the understanding of the disease , its therapy and the life expectancy of those affected .
30160022	This	 changes	  change	the understanding of the disease	0.38	This changes the understanding of the disease , its therapy and the life expectancy of those affected .
30160022	This	 changes	  change	the life expectancy of those	0.23	This changes the understanding of the disease , its therapy and the life expectancy of those affected .
30160022	This	 changes	  change	its therapy	0.02	This changes the understanding of the disease , its therapy and the life expectancy of those affected .
30160031	This work	 focuses	  focus	on radiation therapy	0.98	This work focuses on radiation therapy , a treatment option with possible short- and long-term complications , and the resulting consequences for the patients ' quality of life .
30160031	This work	 focuses	  focus	on the resulting consequences for the patients ' quality of life	0.46	This work focuses on radiation therapy , a treatment option with possible short- and long-term complications , and the resulting consequences for the patients ' quality of life .
30160032	The focus here	 will be	  will be	on radiation treatment	1.00	The focus here will be on radiation treatment , a treatment option with potential short- and long-term complications and the resulting consequences for patients ' quality of life .
30160041	which supportive measures	 can be taken	  can be take	after radiation therapy with the help of clinical pharmacists	0.68	Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists .
30160041	we	 show	  show	which supportive measures can be taken during radiation therapy with the help of clinical pharmacists	0.54	Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists .
30160041	we	 show	  show	which supportive measures can be taken after radiation therapy with the help of clinical pharmacists	0.51	Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists .
30160041	which supportive measures	 can be taken	  can be take	during radiation therapy with the help of clinical pharmacists	0.47	Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists .
30160042	it	 will be shown	  will be show		0.94	Furthermore , it will be shown which supportive measures can be taken during and after radiation treatment with the participation of clinical pharmacists .
30160042	which supportive measures	 can be taken	  can be take	after radiation treatment with the participation of clinical pharmacists	0.72	Furthermore , it will be shown which supportive measures can be taken during and after radiation treatment with the participation of clinical pharmacists .
30160042	which supportive measures	 can be taken	  can be take	during radiation treatment with the participation of clinical pharmacists	0.50	Furthermore , it will be shown which supportive measures can be taken during and after radiation treatment with the participation of clinical pharmacists .
30170001	Daunorubicin	 has been established	  have be establish	as important cornerstone in ALL- and AML-treatment since many years	0.98	Daunorubicin has been established as important cornerstone in ALL- and AML-treatment since many years .
30170002	The anthracycline daunorubicin	 has been	  have be	an integral part of ALL treatment for many years	0.59	The anthracycline daunorubicin has been an integral part of ALL and AML treatment for many years .
30170002	The anthracycline daunorubicin	 has been	  have be	an integral part of AML treatment for many years	0.58	The anthracycline daunorubicin has been an integral part of ALL and AML treatment for many years .
30170011	Its metabolite daunorubicinol	 does not contribute	  doe not contribute	to antineoplastic activities of the anthracycline	0.98	Its metabolite daunorubicinol does not contribute to antineoplastic activities of the anthracycline , however , it may have a potential impact on drug 's cardiotoxicity .
30170011	it	 may have	  may have	a potential impact on drug 's cardiotoxicity	0.97	Its metabolite daunorubicinol does not contribute to antineoplastic activities of the anthracycline , however , it may have a potential impact on drug 's cardiotoxicity .
30170012	The metabolite daunorubicinol	 plays	  play	less of a role in the antineoplastic effect	0.99	The metabolite daunorubicinol plays less of a role in the antineoplastic effect , but probably more in the potential cardiotoxicity of the cytostatic .
30170012	The metabolite daunorubicinol	 plays	  play	more in the potential cardiotoxicity of the cytostatic	0.57	The metabolite daunorubicinol plays less of a role in the antineoplastic effect , but probably more in the potential cardiotoxicity of the cytostatic .
30170021	Current guidelines in Germany	 consider	  consider	a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min	0.93	Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .
30170021	30 and 50 ml/min	 is	  be	in contrast to FDA-based guidelines	0.84	Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .
30170021	the clinical pharmacokinetic behaviour of doxorubicin	 are compared	  be compare	with each other	0.73	Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .
30170021	the clinical pharmacokinetic behaviour of daunorubicin	 are compared	  be compare	with each other	0.72	Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .
30170021	30 and 50 ml/min	 is	  be	somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin are compared with each other	0.64	Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .
30170022	The currently filed guidelines for dose modification	 stipulate	  stipulate	that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min	0.99	The currently filed guidelines for dose modification stipulate that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min .
30170022	the anthracycline	 should only be used	  should only be use	at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min	0.98	The currently filed guidelines for dose modification stipulate that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min .
30170031	a leukemia patient	 may receive	  may receive	daunorubicin full dose in the US	0.96	As a consequence , a leukemia patient may receive daunorubicin full dose in the US , and 50 % of curative dose in Germany in case of e.g . GFR 43 ml/min .
30170031	a leukemia patient	 may 50	  may 50	% of curative dose in Germany in case of . GFR 43 e.g ml/min	0.09	As a consequence , a leukemia patient may receive daunorubicin full dose in the US , and 50 % of curative dose in Germany in case of e.g . GFR 43 ml/min .
30170032	the FDA	 has not provided	  have not provide	a corresponding recommendation to date	0.93	This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .
30170032	This requirement	 is	  be	irritating	0.92	This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .
30170032	This requirement	 considering	  consider	that ( 1 ) the FDA has not provided a corresponding recommendation to date	0.83	This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .
30170032	( 2 ) recent work	 has identified	  have identify	very large clinical pharmacokinetic parallels between daunorubicin	0.67	This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .
30170032	( 2 ) recent work	 has identified	  have identify	very large clinical pharmacokinetic parallels between doxorubicin	0.59	This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .
30170041	a revised assessment of current guidelines on a regulatory level	 is	  be	of great interest for clinical oncologist	1.00	Thus , a revised assessment of current guidelines on a regulatory level is of great interest for clinical oncologist .
30170042	a leukemia patient with a GFR of 43 ml/min	 would receive	  would receive	only 50 % of the curatively scheduled dose in Germany compared States	0.50	Thus , a leukemia patient with a GFR of 43 ml/min would receive only 50 % of the curatively scheduled dose in Germany compared with the United States .
30170052	A timely regulatory reassessment of this issue	 is therefore	  be therefore	of great clinical oncological interest	0.98	A timely regulatory reassessment of this issue is therefore of great clinical oncological interest .
30180001	infections	 involving	  involve	methicillin-resistant Staphylococcus aureus strains	0.97	Vancomycin ( VAN ) is an established treatment option for infections involving methicillin-resistant Staphylococcus aureus strains ( MRSA ) .
30180001	Vancomycin	 is	  be	an established treatment option for infections	0.96	Vancomycin ( VAN ) is an established treatment option for infections involving methicillin-resistant Staphylococcus aureus strains ( MRSA ) .
30180002	Vancomycin	 is	  be	an established therapeutic option for infections with methicillin-resistant Staphylococcus aureus ( MRSA ) strains	1.00	Vancomycin ( VAN ) is an established therapeutic option for infections with methicillin-resistant Staphylococcus aureus ( MRSA ) strains .
30180011	the target	 increased	  increase	of VAN plasma through levels	0.37	However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .
30180011	. the clinical medical societies the target	 ranges	  range	of VAN plasma through levels	0.21	However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .
30180011	both EUCAST Conversely the clinical medical societies	 reduced increased	  reduce increase	the `` sensitive '' MIC range to < 2 mg/L the target ranges of VAN plasma	0.15	However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .
30180011	the bactericidal effect of VAN on MRSA societies	 is reduced	  be reduce	( MICs ) of ≥ 1 mg/L Due to an apparent correlation of VAN MICs with the risk of treatment failure VAN plasma through levels	0.13	However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .
30180011	the bactericidal effect of VAN on MRSA both	 is reduced	  be reduce	strains inhibitory ( MICs ) of ≥ 1 mg/L Due to an apparent correlation of VAN MICs with the risk of treatment failure the `` range to < through levels	0.11	However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .
30180012	the bactericidal effect of VAN on MRSA	 is reduced	  be reduce	for strains already	0.94	However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .
30180012	the MIC of VAN	 increases	  increase	to ≥1 mg/l	0.90	However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .
30180012	clinical societies	 increased	  increase	the target ranges for plasma levels	0.90	However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .
30180012	CLSI	 reduced	  reduce	the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l	0.74	However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .
30180012	strains the MIC of VAN	 increases	  increase	to ≥1 mg/l	0.72	However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .
30180021	ototoxic effects	 limit	  limit	the use of increased VAN dosages for the improvement of treatment efficacy	0.77	However , nephrotoxic and ototoxic effects limit the use of increased VAN dosages for the improvement of treatment efficacy .
30180021	nephrotoxic effects	 limit	  limit	the use of increased VAN dosages for the improvement of treatment efficacy	0.51	However , nephrotoxic and ototoxic effects limit the use of increased VAN dosages for the improvement of treatment efficacy .
30180022	ototoxic effects	 limit	  limit	VAN dose increases to improve therapy	0.75	However , nephro- and ototoxic effects limit VAN dose increases to improve therapy .
30180022	nephro- effects	 limit	  limit	VAN dose increases to improve therapy	0.38	However , nephro- and ototoxic effects limit VAN dose increases to improve therapy .
30180031	Trough level monitoring	 are recommended	  be recommend	for the optimization of VAN exposure	0.59	Trough level monitoring and corresponding dose adjustments are recommended for the optimization of VAN exposure .
30180031	corresponding dose adjustments	 are recommended	  be recommend	for the optimization of VAN exposure	0.59	Trough level monitoring and corresponding dose adjustments are recommended for the optimization of VAN exposure .
30180032	Valley level measurements after therapy initiation , with dose adjustment if necessary	 to optimize	  to optimize	VAN exposure	0.90	Valley level measurements after therapy initiation , with dose adjustment if necessary , are recommended to optimize VAN exposure .
30180032	Valley level measurements after therapy initiation , with dose adjustment necessary	 are recommended	  be recommend	to optimize VAN exposure	0.62	Valley level measurements after therapy initiation , with dose adjustment if necessary , are recommended to optimize VAN exposure .
30180041	the impact of patient characteristics on the attainment of the newly defined target	 ranges	  range	until day 3	0.54	Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .
30180041	we	 investigated	  investigate	the impact of patient characteristics on the attainment of the newly defined target ranges until day 3	0.50	Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .
30180041	the impact of patient characteristics on the attainment of the newly defined target	 ranges	  range	later in the course of treatment	0.46	Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .
30180041	we	 investigated	  investigate	the impact of patient characteristics on the attainment of the newly defined target ranges	0.45	Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .
30180041	the impact of dose regimens on the attainment of the newly defined target	 ranges	  range	until day 3	0.43	Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .
30180042	we	 retrospectively examined	  retrospectively examine	the influences of patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3	0.55	Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .
30180042	the influences of patient characteristics on the achievability of newly defined target	 ranges	  range	for VAN valley levels by therapy day 3	0.51	Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .
30180042	we	 retrospectively examined	  retrospectively examine	the influences of dosing regimens on the achievability of newly defined target ranges for VAN valley levels by	0.46	Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .
30180042	we	 retrospectively examined	  retrospectively examine	the influences of patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day later	0.41	Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .
30180042	we	 retrospectively examined	  retrospectively examine	the influences of dosing regimens on the achievability of newly defined target ranges for VAN valley levels by therapy day later	0.38	Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .
30180051	dosages	 recommended	  recommend	by the manufacturers	0.93	With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment .
30180051	the mean trough levels	 remained clearly	  remain clearly	below the values	0.93	With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment .
30180051	the values	 recommended	  recommend	by current therapeutic guidelines	0.91	With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment .
30180052	mean valley levels	 were	  be	significantly below the current guideline recommendation When dosed according to manufacturer 's instructions	0.65	When dosed according to manufacturer 's instructions , mean valley levels were significantly below the current guideline recommendation ( 15-20 mg/l for severe infections ) , particularly in renally healthy patients .
30180061	only a minority of patients	 reached	  reach	plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three Even with body-weight adjusted dosages	0.98	Even with body-weight adjusted dosages , only a minority of patients reached plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three .
30180061	plasma levels	 meet	  meet	the guideline recommendations , particularly during the early phase of treatment until day three	0.97	Even with body-weight adjusted dosages , only a minority of patients reached plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three .
30180062	only a minority of patients	 achieved	  achieve	valley levels Even with body-weight-based dosing in line with recommendations , especially by therapy day 3	0.54	Even with body-weight-based dosing , only a minority of patients achieved valley levels in line with recommendations , especially by therapy day 3 .
30180071	A moderate correlation	 was observed	  be observe	between VAN trough levels and body weight-adjusted dosage	1.00	A moderate correlation was observed between VAN trough levels and body weight-adjusted dosage .
30180072	a moderate correlation	 of	  of	valley level with body-weight-based dosing	0.53	There was a moderate correlation of valley level with body-weight-based dosing .
30180081	The intraindividual variability of renal function	 confounds	  confound	the predictability of VAN exposure	0.97	The intraindividual variability of renal function which is commonly observed in intensive care patients further confounds the predictability of VAN exposure .
30180081	renal function	 is commonly observed	  be commonly observe	in intensive care patients	0.96	The intraindividual variability of renal function which is commonly observed in intensive care patients further confounds the predictability of VAN exposure .
30180082	more frequent fluctuations in renal function	 have	  have	unpredictable effects on VAN exposure In ICU patients	1.00	In ICU patients , more frequent fluctuations in renal function have unpredictable effects on VAN exposure .
30180091	VAN dosages beyond the manufacturer recommendation	 are required	  be require	to reach the target trough levels In most cases	0.96	In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) .
30180091	the target trough levels	 specified	  specify	by the guidelines	0.93	In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) .
30180091	VAN dosages beyond the manufacturer recommendation	 to reach	  to reach	the target trough levels specified by the guidelines	0.91	In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) .
30180092	VAN doses above the manufacturer 's recommendation	 are needed	  be need	In most cases to achieve the current valley level target of 10 to	0.32	In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients .
30180092	mg/l The results	 ranges	  range		0.06	In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients .
30180092	VAN doses above the manufacturer 's recommendation	 are needed achieve	  be need achieve	to the current valley level target of to results In most cases	0.04	In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients .
30180092	doses above current valley level . The results	 ranges argue	  range argue	10 to 20 mg/l for early , repeated valley level measurements even in renally healthy patients	0.04	In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients .
30180101	These results	 strongly support	  strongly support	repeated VAN trough level measurements even in patients with normal renal function	0.58	These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .
30180101	early VAN	 trough	  trough	level measurements even in patients with normal renal function	0.53	These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .
30180101	These results	 strongly support	  strongly support	early VAN trough level measurements in patients with normal function even renal	0.02	These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .
30180102	The low exposure in the critical early phase	 suggest	  suggest	the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens	0.61	The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .
30180102	The low exposure in the critical early phase	 suggest	  suggest	the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens	0.59	The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .
30180102	the limited correlation of dosage	 suggest	  suggest	the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens	0.42	The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .
30180102	the limited correlation of exposure	 suggest	  suggest	the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens	0.42	The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .
30180102	the limited correlation of dosage	 suggest	  suggest	the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens	0.39	The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .
30180111	the generally low exposure	 observed	  observe	in the critical early phase	0.89	Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
30180111	VAN MIC	 ≥	  ≥	2 mg/L	0.85	Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
30180111	the generally low exposure observed in the critical early phase	 suggest	  suggest	the use of other antibiotics active against MRSA	0.79	Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
30180111	the generally low exposure	 observed	  observe	in the critical early phase	0.89	Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
30180111	VAN MIC	 ≥	  ≥	2 mg/L	0.85	Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
30180111	the generally low exposure observed in the critical early phase	 suggest	  suggest	the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs	0.64	Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
30180111	the generally low exposure observed in the critical early phase	 suggest	  suggest	the use of other antibiotics active against MRSA at least in severely ill patients with infections of deep tissues	0.60	Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
30180111	the limited correlation of exposure	 suggest	  suggest	the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs	0.38	Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
30180112	the occurrence of toxicity	 have not been studied	  have not be study		0.54	However , the clinical and microbiological response and the occurrence of toxicity have not been studied .
30180112	the microbiological response	 have not been studied	  have not be study		0.15	However , the clinical and microbiological response and the occurrence of toxicity have not been studied .
30180112	the clinical response	 have not been studied	  have not be study		0.06	However , the clinical and microbiological response and the occurrence of toxicity have not been studied .
30180121	microbiological responses as well as toxicities	 were not investigated	  be not investigate	in this study	0.66	Clinical and microbiological responses as well as toxicities were not investigated in this study .
30180121	Clinical responses as well as toxicities	 were not investigated	  be not investigate	in this study	0.20	Clinical and microbiological responses as well as toxicities were not investigated in this study .
30190001	ceftazidime	 are commonly used	  be commonly use	broad spectrum beta-lactam antibiotics in intensive care units	0.74	Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units .
30190001	Meropenem	 are commonly used	  be commonly use	broad spectrum beta-lactam antibiotics in intensive care units	0.67	Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units .
30190001	piperacillin	 are commonly used	  be commonly use	broad spectrum beta-lactam antibiotics in intensive care units	0.61	Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units .
30190002	The beta-lactam antibiotics meropenem	 are used	  be use	in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity	0.76	The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity .
30190002	The beta-lactam antibiotics ceftazidime	 are used	  be use	in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity	0.71	The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity .
30190002	The beta-lactam antibiotics piperacillin	 are used	  be use	in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity	0.54	The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity .
30190011	To improve the therapeutic outcome of the antimicrobial therapy of critically ill patients therapeutic drug monitoring	 is recommended	  be recommend		0.93	To improve the therapeutic outcome of the antimicrobial therapy of critically ill patients therapeutic drug monitoring is recommended .
30190012	the establishment of therapeutic drug monitoring	 is recommended	  be recommend	to improve therapeutic outcome	0.97	Due to strong inter- and intraindividual variations in pharmacokinetics , the establishment of therapeutic drug monitoring is recommended to improve therapeutic outcome .
30190012	the establishment of therapeutic drug monitoring	 to improve	  to improve	therapeutic outcome	0.95	Due to strong inter- and intraindividual variations in pharmacokinetics , the establishment of therapeutic drug monitoring is recommended to improve therapeutic outcome .
30190021	an analytical method	 measuring	  measure	fluctuating serum levels during therapy	0.96	Therefore an analytical method was established measuring fluctuating serum levels during therapy .
30190021	an analytical method	 was established	  be establish	measuring fluctuating serum levels during therapy	0.95	Therefore an analytical method was established measuring fluctuating serum levels during therapy .
30190022	an analytical HPLC method	 is described	  be describe	In the following	0.99	In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .
30190022	which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml	 can be determined quickly	  can be determine quickly		0.79	In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .
30190022	an analytical HPLC method	 is described	  be describe	In the following	0.99	In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .
30190022	which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml	 can be determined reliably	  can be determine reliably		0.59	In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .
30190031	A sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection	 was developed	  be develope	for simultaneous quantification of these antimicrobial agents	0.60	A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .
30190031	A sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection	 was validated	  be validate	for simultaneous quantification of these antimicrobial agents	0.56	A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .
30190031	A simple high-performance liquid chromatography ( HPLC ) method with diode array detection	 was developed	  be develope	for simultaneous quantification of these antimicrobial agents	0.55	A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .
30190031	A simple high-performance liquid chromatography ( HPLC ) method with diode array detection	 was validated	  be validate	for simultaneous quantification of these antimicrobial agents	0.51	A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .
30190032	The serum levels determined	 can be used	  can be use	as a valid basis for further therapy decisions then	0.98	The serum levels determined can then be used as a valid basis for further therapy decisions .
30190032	The serum levels	 determined	  determine		0.90	The serum levels determined can then be used as a valid basis for further therapy decisions .
30190041	a sample amount of 250 µl serum	 was spiked	  be spike	with cefotaxime as an internal standard For sample preparation	0.99	For sample preparation a sample amount of 250 µl serum was spiked with cefotaxime as an internal standard .
30190051	protein	 was precipitated	  be precipitate	Afterwards	0.94	Afterwards protein was precipitated using acetonitrile/methanol ( 1:1 ) .
30190061	The supernatant	 was transferred	  be transfer	to HPLC	1.00	The supernatant was transferred to HPLC .
30190071	A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a pH 2.2 phosphoric acid solution	 was used	  be use	for separation	0.80	A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile and a pH 2.2 phosphoric acid solution was used for separation .
30190071	A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile	 was used	  be use	for separation	0.74	A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile and a pH 2.2 phosphoric acid solution was used for separation .
30190081	Peaks of interest	 were detected respectively	  be detect respectively	at 240 nm	0.34	Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively .
30190081	Peaks of interest	 were detected respectively	  be detect respectively	at 310 nm	0.26	Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively .
30190081	Peaks of interest	 were detected respectively	  be detect respectively	at 298 nm	0.16	Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively .
30190091	The method	 developed	  develope		0.89	The method developed shows a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml for each antibiotic in the serum samples .
30190091	The method developed	 shows	  show	a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml	0.80	The method developed shows a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml for each antibiotic in the serum samples .
30190101	the method	 to be too	  to be too	accurate	0.61	Validation has demonstrated the method to be accurate and precise too .
30190101	Validation	 has demonstrated	  have demonstrate	the method to be accurate too	0.44	Validation has demonstrated the method to be accurate and precise too .
30190101	Validation	 has demonstrated	  have demonstrate	the method to be precise too	0.36	Validation has demonstrated the method to be accurate and precise too .
30190101	the method	 to be too	  to be too	precise	0.30	Validation has demonstrated the method to be accurate and precise too .
30190111	No interferences with other common drugs except metamizole	 were detected	  be detect		0.65	No interferences with other common drugs except metamizole ( dipyrone ) and ceftazidime were detected .
30190111	No interferences with other common drugs except ceftazidime	 were detected	  be detect		0.42	No interferences with other common drugs except metamizole ( dipyrone ) and ceftazidime were detected .
30190121	The method	 is used	  be use	in the pharmacy department of the German Army Hospital in Berlin for therapeutic drug monitoring ( TDM ) of beta-lactams in critically ill patients currently	1.00	The method is currently used in the pharmacy department of the German Army Hospital in Berlin for therapeutic drug monitoring ( TDM ) of beta-lactams in critically ill patients .
30200001	The frequency of bacterial infections	 is increasing	  be increase	worldwide due to the development of antibiotic resistance among pathogens	0.94	The frequency of bacterial infections for which antibiotics no longer work is increasing worldwide due to the development of antibiotic resistance among pathogens .
30200002	The frequency of bacterial infections	 is increasing	  be increase	worldwide due to the development of resistance in pathogens	0.96	The frequency of bacterial infections for which antibiotics are no longer effective is increasing worldwide due to the development of resistance in pathogens .
30200002	bacterial infections	 are	  be	antibiotics no longer effective	0.47	The frequency of bacterial infections for which antibiotics are no longer effective is increasing worldwide due to the development of resistance in pathogens .
30200011	Research topics , in order	 include	  include	the development of new antibiotics	0.88	Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances .
30200011	Research topics , in order	 include	  include	the finding of resistance-modifying properties of natural substances	0.62	Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances .
30200011	Research topics , in order	 include	  include	the reactivation of existing antibacterial agents	0.44	Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances .
30200012	research	 is being conducted	  be be conduct	To counter this threat in addition to the development of new antibiotics and the reactivation of existing antibacterial agents - into the resistance-modifying properties of natural products	0.75	To counter this threat , research is being conducted - in addition to the development of new antibiotics and the reactivation of existing antibacterial agents - into the resistance-modifying properties of natural products .
30200021	the checkerboard microdilution method	 was used	  be use	to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens In the present work	0.76	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .
30200021	the checkerboard microdilution method	 was used	  be use	to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens In the present work	0.73	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .
30200021	the checkerboard microdilution method	 to investigate	  to investigate	how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens pneumoniae	0.68	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .
30200021	the checkerboard microdilution method	 was used	  be use	to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae In the present work	0.67	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .
30200021	the checkerboard microdilution method	 was used	  be use	to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens In the present work	0.65	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .
30200022	the checkerboard microdilution method	 was used	  be use	to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens , respectively In the present work	0.73	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .
30200022	the checkerboard microdilution method	 was used	  be use	to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens In the present work	0.72	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .
30200022	the checkerboard microdilution method	 was used	  be use	to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens respectively In the present work	0.70	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .
30200022	the checkerboard microdilution method	 to investigate	  to investigate	how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens	0.68	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .
30200022	the checkerboard microdilution method	 was used	  be use	to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens , respectively In the present work	0.68	In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .
30200031	the essential oils of both plant species	 reduce	  reduce	the minimum inhibitory concentrations of imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species	0.90	The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200031	The results	 indicate	  indicate	that the essential oils of both plant species reduce the minimum inhibitory concentrations of imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species	0.88	The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200031	the essential oils of both plant species	 significantly increase	  significantly increase	the antibiotic effects	0.78	The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200031	The results	 indicate	  indicate	that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin against multi-drug resistant clinical isolates of the two gram-negative bacterial species	0.69	The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200031	the essential oils of both plant species	 reduce	  reduce	the minimum inhibitory concentrations of gentamicin against multi-drug resistant clinical isolates of the two gram-negative bacterial species	0.69	The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200032	The results	 show	  show	that the essential oils of both plant species decrease the minimum inhibitory concentrations of imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species	0.91	The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .
30200032	the essential oils of both plant species	 decrease	  decrease	the minimum inhibitory concentrations of imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species	0.91	The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .
30200032	the essential oils of both plant species	 significantly enhancing	  significantly enhance	antibiotic efficacy	0.74	The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .
30200032	The results	 show	  show	that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin against multidrug-resistant clinical isolates of the two Gram-negative bacterial species	0.72	The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .
30200032	the essential oils of both plant species	 decrease	  decrease	the minimum inhibitory concentrations of gentamicin against multidrug-resistant clinical isolates of the two Gram-negative bacterial species	0.71	The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .
30200041	The observed potent resistance-modifying properties of the essential oils	 favour	  favour	further investigations of the phenylpropanoids as the main components of both oils in this context	0.74	The observed potent resistance-modifying properties of the essential oils favour further investigations of the phenylpropanoids as the main components of both oils and other natural substances in this context .
30200041	The observed potent resistance-modifying properties of the essential oils	 favour	  favour	further investigations of the phenylpropanoids as the main components of both other natural substances in this context	0.57	The observed potent resistance-modifying properties of the essential oils favour further investigations of the phenylpropanoids as the main components of both oils and other natural substances in this context .
30200042	The potent resistance-modifying properties of the essential oils	 suggest	  suggest	further investigation of phenylpropanoids as major components of both oils in this context is promising	0.74	The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .
30200042	The potent resistance-modifying properties of the essential oils	 suggest	  suggest	further investigation of phenylpropanoids as major components of both other natural products in this context is promising	0.60	The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .
30200042	further investigation of phenylpropanoids as major components of both oils in this context	 is	  be	promising	0.54	The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .
30200042	further investigation of phenylpropanoids as major components of both other natural products in this context	 is	  be	promising	0.42	The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .
30210001	substances	 are	  be	already available	0.93	Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available .
30210001	researchers	 are looking	  be look	for effective therapy in substances	0.43	Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available .
30210001	researchers	 are looking	  be look	for promising therapy in substances	0.28	Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available .
30210002	research	 is looking	  be look	for promising , effective substances	0.96	Since there is still no reliable therapy and not enough approved vaccines against SARS-CoV-2 , research is looking for promising , effective substances that are already available .
30210002	promising , effective substances	 are	  be	already available	0.94	Since there is still no reliable therapy and not enough approved vaccines against SARS-CoV-2 , research is looking for promising , effective substances that are already available .
30210011	The objective of the current study	 is	  be	to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2	0.98	The objective of the current study is to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2 .
30210011	the herbal preparation	 has	  have	in vitro antiviral properties	0.67	The objective of the current study is to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2 .
30210012	This study	 will investigate	  will investigate	whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2	0.96	This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses .
30210012	the herbal preparation	 has	  have	in vitro antiviral properties against SARS-CoV-2	0.94	This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses .
30210012	it	 to be	  to be	antiviral properties against SARS-CoV-2 effective against several other viruses	0.20	This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses .
30210012	it	 has been shown	  have be show	effective against other viruses already	0.15	This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses .
30210021	CPE	 to be	  to be	effective against several other viruses	0.95	CPE has already proved to be effective against several other viruses .
30210021	CPE	 has proved	  have prove	already	0.94	CPE has already proved to be effective against several other viruses .
30210022	the reduction in infection rate	 by comparing	  by compare	foci-forming units	0.89	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .
30210022	cell cultures	 were infected	  be infect	with SARS-CoV-2 At the Fraunhofer Institute for Cell Therapy	0.74	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .
30210022	the reduction in infection rate	 was evaluated	  be evaluate	by comparing foci-forming units At the Fraunhofer Institute for Immunology	0.74	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .
30210022	cell cultures	 using	  use	Cystus Pandalis® extract	0.69	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .
30210022	cell cultures	 were infected	  be infect	with SARS-CoV-2 using Cystus Pandalis® At the Fraunhofer Institute for Immunology	0.66	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .
30210031	cell cultures	 treated	  treat	with Cystus Pandalis® extract	0.91	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .
30210031	the reduction in the infection rate	 was evaluated	  be evaluate	by comparing focus-forming units At the Fraunhofer Institute for Immunology	0.74	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .
30210031	the reduction in the infection rate	 was evaluated	  be evaluate	by comparing focus-forming units At the Fraunhofer Institute for Cell Therapy	0.69	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .
30210031	IZI ) cell cultures treated with Cystus Pandalis® extract	 were infected	  be infect	with SARS-CoV-2 At the Fraunhofer Institute for Immunology	0.55	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .
30210031	( IZI ) cell cultures treated with Cystus Pandalis® extract	 were infected	  be infect	with SARS-CoV-2 At the Fraunhofer Institute for Cell Therapy	0.51	At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .
30210032	An almost complete reduction in infection rate by CPE	 was observed	  be observe	at concentrations greater than 15.6 µg/ml with a calculated EC50 of 1.94 µg/ml	1.00	An almost complete reduction in infection rate by CPE was observed at concentrations greater than 15.6 µg/ml with a calculated EC50 of 1.94 µg/ml .
30210041	An almost complete reduction in the CPE infection rate	 was observed	  be observe	at concentrations of greater than 15.6 µg/ml with a calculated EC50 ( mean effective concentration ) of 1.94 µg/ml	1.00	An almost complete reduction in the CPE infection rate was observed at concentrations of greater than 15.6 µg/ml with a calculated EC50 ( mean effective concentration ) of 1.94 µg/ml .
30210042	The mechanism of action of this extract	 may be based	  may be base	on the high polymer polyphenols	0.95	The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor .
30210042	the high polymer polyphenols	 coat	  coat	certain viral epitopes	0.94	The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor .
30210042	CPE	 to act	  to act	as an entry inhibitor	0.92	The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor .
30210042	the high polymer polyphenols that ,	 certain viral epitopes causing	  certain viral epitope cause	CPE to act as an entry inhibitor	0.19	The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor .
30210051	The mechanism of action of this extract	 may be based	  may be base	on the highly polymeric polyphenols	0.96	The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor .
30210051	CPE	 acts	  act	as an entry inhibitor	0.92	The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor .
30210051	the highly polymeric polyphenols	 envelop	  envelop	certain viral epitopes , whereby CPE acts as an entry inhibitor	0.88	The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor .
30210052	it	 to use	  to use	CPE as prophylaxis against infections with SARS-CoV-2	0.91	Due to the high in vitro activity , it seems reasonable to use CPE as prophylaxis against infections with SARS-CoV-2 .
30210061	The high in vitro activity of CPE	 to make	  to make	it a reasonable candidate for prophylaxis against SARS-CoV-2	0.98	The high in vitro activity of CPE seems to make it a reasonable candidate for prophylaxis against SARS-CoV-2 .
30210061	The high in vitro activity of CPE	 seems	  seem		0.97	The high in vitro activity of CPE seems to make it a reasonable candidate for prophylaxis against SARS-CoV-2 .
30220001	Fruits from Apium graveolens	 are used traditionally	  be use traditionally	in European medicine for the treatment of uncomplicated urinary tract infections	0.60	Fruits from Apium graveolens ( celery ) are used traditionally in Persian and European medicine for the treatment of uncomplicated urinary tract infections .
30220001	Fruits from Apium graveolens	 are used traditionally	  be use traditionally	in Persian medicine for the treatment of uncomplicated urinary tract infections	0.47	Fruits from Apium graveolens ( celery ) are used traditionally in Persian and European medicine for the treatment of uncomplicated urinary tract infections .
30220002	The fruits of Apium graveolens L.	 are used	  be use	in traditional European medicine for the treatment of uncomplicated urinary tract infections	0.53	The fruits of Apium graveolens L. ( celery ) are used in traditional Persian and European medicine for the treatment of uncomplicated urinary tract infections ( UTI ) .
30220002	The fruits of Apium graveolens L.	 are used	  be use	in traditional Persian medicine for the treatment of uncomplicated urinary tract infections	0.52	The fruits of Apium graveolens L. ( celery ) are used in traditional Persian and European medicine for the treatment of uncomplicated urinary tract infections ( UTI ) .
30220011	No data	 are	  be	available on A. graveolens extract on the interplay between uropathogenic E. coli	0.66	No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .
30220011	No data	 are	  be	available on A. graveolens extract on the interplay between the eukaryotic host cells	0.58	No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .
30220011	No data	 are	  be	available on A. graveolens on sensing of the bacteria extract quorum	0.04	No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .
30220012	no data	 investigating	  investigate	the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bacterial quorum sensing	0.74	To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .
30220012	no data	 investigating	  investigate	the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder	0.66	To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .
30220012	no data	 investigating	  investigate	the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from kidney	0.50	To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .
30220012	no data	 are	  be	available investigating influence of corresponding drug extracts with regard To date	0.18	To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .
30220012	no data	 are	  be	available investigating influence of corresponding drug extracts with regard to To date	0.11	To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .
30220021	The present study	 aimed	  aim	to characterize an anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays	0.58	The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220021	The present study	 aimed	  aim	to characterize an antiadhesive effect of a characterized A. graveolens extract by specific in vitro assays	0.56	The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220021	The present study	 aimed to characterize	  aim to characterize	an anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays	0.54	The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220021	The present study	 aimed to characterize	  aim to characterize	an antiadhesive effect of a characterized A. graveolens extract by specific in vitro assays	0.53	The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220021	The present study	 aimed to	  aim to	correlate these effects with in vivo data	0.23	The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220022	A. graveolens	 using	  use	in vitro studies	0.75	The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220022	The present studies	 describe	  describe	a marked anti-adhesive effect of an extract of A. graveolens	0.46	The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220022	The present studies	 describe	  describe	a marked anti-quorum sensing effect of an extract of A. graveolens	0.62	The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220022	A. graveolens	 using	  use	in vivo studies in the mouse infection model	0.54	The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220022	The present studies	 describe	  describe	a marked anti-adhesive effect of an extract of A. graveolens	0.46	The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220022	A. graveolens	 sensing using	  sense use	in vivo studies in the mouse infection model	0.17	The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220031	Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits	 was characterized	  be characterize	by UHPLC/+ESI-QTOF-MS	0.97	Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells .
30220031	Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits	 was investigated	  be investigate	on antiproliferative activity against UPEC	0.72	Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells .
30220031	Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits	 was investigated	  be investigate	on antiproliferative activity against human T24 bladder cells	0.57	Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells .
30220032	A hydroalcoholic extract EtOH-water , 1:1 ) of A. graveolens fruit	 was phytochemically characterized	  be phytochemically characterize	by UHPLC/+ESI-QTOF-MS	0.87	A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells .
30220032	extract EtOH-water , 1:1 ) of A. graveolens fruit	 was evaluated	  be evaluate	for antiproliferative properties against UPEC ( strain	0.42	A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells .
30220032	extract 	 EtOH-water , 1:1 ) of A. graveolens fruit	  EtOH - water , 1:1 ) of A. graveolens fruit	was evaluated; for antiproliferative properties against human T24 blast cells	0.31	A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells .
30220041	Antiadhesive properties of CSE	 were investigated	  be investigate	within two different in vitro adhesion assays	1.00	Antiadhesive properties of CSE were investigated within two different in vitro adhesion assays .
30220042	Anti-adhesive effects of CSE	 were tested	  be test	by two in vitro adhesion assays	1.00	Anti-adhesive effects of CSE were tested by two in vitro adhesion assays .
30220051	BALB/c mice	 were used	  be use	in an UPEC infection model For in vivo studies	1.00	For in vivo studies BALB/c mice were used in an UPEC infection model .
30220052	BALB/c mice	 were used	  be use	in a UPEC infection model For in vivo studies	0.87	For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .
30220052	the effect of CSE on bacterial load in kidney tissues	 was investigated	  be investigate	in the context of 7-day pretreatment For in vivo studies	0.39	For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .
30220052	the effect of CSE on bacterial load in bladder tissues	 was investigated respectively	  be investigate respectively	in the context of 7-day pretreatment For in vivo studies	0.35	For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .
30220052	the effect of CSE on bacterial load in kidney tissues	 was investigated respectively	  be investigate respectively	in the context of 4- pretreatment For in vivo studies	0.34	For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .
30220052	the effect of CSE on bacterial load in bladder tissues	 was investigated respectively	  be investigate respectively	in the context of 4- pretreatment For in vivo studies	0.32	For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .
30220061	The effect of CSE on bacterial load in bladder tissue	 was monitored	  be monitor	within a 4- days pretreatment	0.42	The effect of CSE on bacterial load in bladder tissue was monitored within a 4- and 7 days pretreatment ( 200 , 500 mg/kg ) of the animals .
30220061	The effect of CSE on bacterial load in bladder tissue	 was monitored	  be monitor	within a 7 days pretreatment the	0.20	The effect of CSE on bacterial load in bladder tissue was monitored within a 4- and 7 days pretreatment ( 200 , 500 mg/kg ) of the animals .
30220062	CSE	 is phytochemically characterized	  be phytochemically characterize	by the presence of luteolin glycosides	0.71	CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins .
30220062	CSE	 is phytochemically characterized	  be phytochemically characterize	by the presence of similar flavones	0.37	CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins .
30220062	CSE	 is phytochemically characterized	  be phytochemically characterize	by the presence of furanocoumarins	0.22	CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins .
30220071	CSE	 was dominated	  be dominate	by the presence of luteolin-glycosides besides furocoumarins	0.75	CSE was dominated by the presence of luteolin-glycosides and related flavones besides furocoumarins .
30220071	CSE	 was dominated	  be dominate	by the presence of related flavones besides furocoumarins	0.37	CSE was dominated by the presence of luteolin-glycosides and related flavones besides furocoumarins .
30220072	CSE	 exhibits	  exhibit	concentration-dependent antiadhesive effects against UPEC strain	0.60	CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 .
30220072	CSE	 shows	  show	no cytotoxic effects against UPEC	0.53	CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 .
30220072	CSE	 shows	  show	no cytotoxic effects against blast cells	0.50	CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 .
30220072	CSE	 exhibits	  exhibit	concentration-dependent antiadhesive effects against UTI89	0.39	CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 .
30220081	CSE	 had	  have	no cytotoxic effects against UPEC	0.49	CSE had no cytotoxic effects against UPEC and bladder cells .
30220081	CSE	 had	  have	no cytotoxic effects against bladder cells	0.33	CSE had no cytotoxic effects against UPEC and bladder cells .
30220082	CSE	 inhibits	  inhibit	bacterial quorum sensing in a concentration-dependent manner	0.98	CSE inhibits bacterial quorum sensing in a concentration-dependent manner .
30220091	CSE	 exerts	  exert	a dose dependent antiadhesive activity against UPEC	0.99	CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .
30220091	a dose dependent antiadhesive activity against UPEC	 strains	  strain	NU14	0.42	CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .
30220091	a dose dependent antiadhesive activity against UPEC	 strains	  strain	UTI89	0.35	CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .
30220092	7 day pretreatment of mice with CSE	 followed	  follow	by transurethal UPEC NU14 infection	0.88	In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .
30220092	4 day pretreatment of mice with CSE	 followed	  follow	by transurethal UPEC NU14 infection	0.43	In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .
30220092	In vivo 4 day pretreatment of mice with CSE	 significantly inhibited	  significantly inhibit	bacterial load in bladder tissue	0.41	In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .
30220092	In vivo 7 day pretreatment of mice with CSE	 significantly inhibited	  significantly inhibit	bacterial load in bladder tissue	0.19	In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .
30220101	CSE	 inhibited	  inhibit	in a concentration-dependent manner	0.88	CSE inhibited in a concentration-dependent manner bacterial quorum sensing .
30220101	a concentration-dependent manner bacterial quorum	 sensing	  sense		0.40	CSE inhibited in a concentration-dependent manner bacterial quorum sensing .
30220102	the traditional use of the drug in UTI	 appears	  appear		0.97	Based on these data , the traditional use of the drug in UTI appears to be justified .
30220102	the traditional use of the drug in UTI	 to be justified	  to be justify		0.96	Based on these data , the traditional use of the drug in UTI appears to be justified .
30220111	CSE	 transurethrally infected	  transurethrally infect	with UPEC NU14	0.96	4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue .
30220111	7-day pretreatment of animals with CSE	 significantly reduced	  significantly reduce	the bacterial load in bladder tissue	0.75	4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue .
30220111	4- pretreatment of animals with CSE	 significantly reduced	  significantly reduce	the bacterial load in bladder tissue	0.59	4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue .
30220121	an antiadhesive extract	 is justified	  be justify	the traditional use in phytotherapy for UTI	0.97	CSE is assessed as an antiadhesive extract for which the traditional use in phytotherapy for UTI is justified .
30220121	CSE	 is assessed	  be assess	as an antiadhesive extract	0.96	CSE is assessed as an antiadhesive extract for which the traditional use in phytotherapy for UTI is justified .
30230001	2- ( 4-Chlorophenyl ) -4-metathiazanone	 is	  be	the intermediate product for the two step-synthesis of chlormezanone (	0.73	2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2 ) is the intermediate product for the two step-synthesis of chlormezanone ( 1 ) , a centrally acting muscle relaxant .
30230002	2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2	 is	  be	the intermediate in the two-step synthesis of chlormezanone (	0.72	2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2 ) is the intermediate in the two-step synthesis of chlormezanone ( 1 ) , a centrally acting muscle relaxant .
30230011	The second step	 includes	  include	the oxidation of its sulfur atom	1.00	The second step includes the oxidation of its sulfur atom .
30230012	The second step	 is	  be	the oxidation of the sulfur atom	1.00	The second step is the oxidation of the sulfur atom .
30230021	the subsequent addition of β-mercaptopropionic acid	 leads	  lead	to a remarkable better yield	0.97	It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )
30230021	methylamine	 forming	  form	the hemiaminale	0.95	It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )
30230021	the foregoing reaction of 4-chlorobenzaldehyde with methylamine	 leads	  lead	to a remarkable better yield	0.79	It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )
30230021	It	 has been found	  have be find		0.73	It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )
30230031	the route via ( 42 % of th . ) .2	 could be oxidized	  can be oxidize	with sodium perborate superior to potassium permanganate hemimercaptale	0.15	than the route via the hemimercaptale ( 42 % of th . ) .2 could be oxidized with sodium perborate superior to potassium permanganate .
30230032	the reverse	 is added	  be add		0.90	of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .
30230032	methylamine	 reacts	  react	with β-mercaptopropionic acid then	0.84	of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .
30230032	4-chlorobenzaldehyde	 reacts	  react	with β-mercaptopropionic acid then	0.58	of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .
30230032	the reverse	 is added	  be add	via the half-mercaptal d.th	0.53	of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .
30230032	the half-aminal	 is formed	  be form	from 4-chlorobenzaldehyde first	0.48	of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .
30230041	The racemic chlormezanone	 is resolved quickly	  be resolve quickly	on a gram scale by preparative column chromatography on a Chiralcel® OD column	0.99	The racemic chlormezanone ( 1 ) is resolved quickly on a gram scale by preparative column chromatography on a Chiralcel® OD column ( tris ( 3,5-dimethyl-phenyl-carbamoyl ) cellulose on silicagel ) .
30230042	Sodium perborate	 is	  be	clearly superior to potassium permanganate as an oxidizing agent	0.99	Sodium perborate is clearly superior to potassium permanganate as an oxidizing agent .
30230042	Sodium perborate	 to	  to	potassium permanganate as an oxidizing agent	0.61	Sodium perborate is clearly superior to potassium permanganate as an oxidizing agent .
30230051	The resolution	 needed	  need	only 40 min	0.94	The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column .
30230051	flow rate	 are determined	  be determine	prior with an analytical column	0.57	The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column .
30230051	temperature as the most important factors	 are determined	  be determine	prior with an analytical column	0.56	The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column .
30230051	composition of the mobile phase	 are determined	  be determine	prior with an analytical column	0.34	The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column .
30230052	The racemic chloromezanone	 can be separated rapidly	  can be separate rapidly	in the grammaÞstab on a Chiralcel® column	0.45	The racemic chloromezanone ( 1 ) can be separated rapidly in the grammaÞstab on a Chiralcel® OD column .
30230061	Both dissociation constants	 could be determined	  can be determine	for the first time with the aid of a log pKa-Titrator of the Sirius Co.	0.98	Both dissociation constants could be determined for the first time with the aid of a log pKa-Titrator of the Sirius Co. , which needs for the registration of the curves only 15–17 min in the pH range of 2–12 .
30230061	the Sirius Co.	 needs	  need	for the registration of the curves only	0.47	Both dissociation constants could be determined for the first time with the aid of a log pKa-Titrator of the Sirius Co. , which needs for the registration of the curves only 15–17 min in the pH range of 2–12 .
30230062	the separation	 requires	  require	only 40 min then	0.96	If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min .
30230062	the crucial factors such as flow rate	 are determined	  be determine	on analytical columns first	0.65	If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min .
30230062	the crucial factors such as temperature	 are determined	  be determine	on analytical columns first	0.25	If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min .
30230062	the crucial factors such as mobile phase composition	 are determined	  be determine	on analytical columns first	0.21	If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min .
30230071	This speed	 outplayed	  outplay	the disturbing cleavage of the S-C bond of chlormezanone at strong acidic pH values	0.39	This speed outplayed the disturbing cleavage of the S-C bond of chlormezanone at strong acidic and alkaline pH values .
30230071	This speed	 outplayed	  outplay	the disturbing cleavage of the S-C bond of chlormezanone at strong alkaline pH values	0.25	This speed outplayed the disturbing cleavage of the S-C bond of chlormezanone at strong acidic and alkaline pH values .
30230072	the log pKa titrator from Sirius Co.	 requires	  require	only 15-17 min to register the titration curves in the pH range 2-12	0.97	For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 .
30230072	the two dissociation constants of 1	 could be determined	  can be determine	For the first time	0.95	For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 .
30230072	only 15-17 min	 to register	  to register	the titration curves in the pH range 2-12	0.81	For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 .
30230082	This speed	 glosses	  gloss	over the interfering break in the S-C bond of 1 in the strongly acidic pH ranges	0.48	This speed glosses over the interfering break in the S-C bond of 1 in the strongly acidic and strongly alkaline pH ranges .
30230082	the interfering break in the S-C bond of 1 in the strongly acidic pH	 ranges	  range		0.40	This speed glosses over the interfering break in the S-C bond of 1 in the strongly acidic and strongly alkaline pH ranges .
30230082	the interfering break in the S-C bond of 1 in the strongly alkaline pH	 ranges	  range		0.36	This speed glosses over the interfering break in the S-C bond of 1 in the strongly acidic and strongly alkaline pH ranges .
30240001	an antiseptic wound powder	 based	  base	on the antibiotic tyrothricin	0.97	Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .
30240001	The tolerance of an antiseptic wound powder	 was investigated	  be investigate	in a prospective , randomized multicenter trial in patients with posttraumatic cutaneous lesions	0.35	Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .
30240001	The efficacy of an antiseptic wound powder	 was investigated	  be investigate	in a prospective , randomized multicenter trial in patients with posttraumatic cutaneous lesions	0.34	Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .
30240001	The tolerance of an antiseptic wound powder	 was investigated	  be investigate	in a prospective , randomized multicenter trial in patients with surgical cutaneous lesions	0.34	Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .
30240001	The efficacy of an antiseptic wound powder	 was investigated	  be investigate	in a prospective , randomized multicenter trial in patients with surgical cutaneous lesions	0.33	Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .
30240002	an antibiotic wound powder	 containing	  contain	the active ingredient tyrothricin	0.97	Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .
30240002	the tolerability of an antibiotic wound powder	 were investigated	  be investigate	in posttraumatic skin lesions In a prospective , randomized multicenter study	0.49	Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .
30240002	the tolerability of an antibiotic wound powder	 were investigated	  be investigate	in postoperative skin lesions In a prospective , randomized multicenter study	0.46	Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .
30240002	the efficacy of an antibiotic wound powder	 were investigated	  be investigate	in posttraumatic skin lesions In a prospective , randomized multicenter study	0.38	Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .
30240002	the efficacy of an antibiotic wound powder	 were investigated	  be investigate	in postoperative skin lesions In a prospective , randomized multicenter study	0.36	Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .
30240011	area	 ≥	  ≥	200 mm2	0.82	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240011	131 male patients from 18–85 years	 were included	  be include	with posttraumatic cutaneous lesions with infection In 5 centers	0.22	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240011	131 male patients from 18–85 years	 were included	  be include	with posttraumatic cutaneous lesions in danger of infection In 5 centers	0.22	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240011	131 female patients from 18–85 years	 were included	  be include	with posttraumatic cutaneous lesions with infection In 5 centers	0.22	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240011	131 female patients from 18–85 years	 were included	  be include	with posttraumatic cutaneous lesions in danger of infection In 5 centers	0.22	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240011	area	 ≥	  ≥	200 mm2	0.82	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240011	131 male patients from 18–85 years	 were included	  be include	with posttraumatic cutaneous lesions in danger of infection In 5 centers	0.22	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240011	131 female patients from 18–85 years	 were included	  be include	with posttraumatic cutaneous lesions with infection In 5 centers	0.22	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240011	131 female patients from 18–85 years	 were included	  be include	with posttraumatic cutaneous lesions in danger of infection In 5 centers	0.22	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240011	131 male patients from 18–85 years	 were included	  be include	with surgical cutaneous lesions in danger of infection In 5 centers	0.20	Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
30240012	131 men aged 18 to 85 years with a infection-prone skin lesion ( wound area ≥ 200 mm2 )	 participated	  participate	In 5 study sites	0.35	PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .
30240012	131 men aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 )	 participated	  participate	In 5 study sites	0.33	PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .
30240012	131 women aged 18 to 85 years with a infection-prone skin lesion ( wound area ≥ 200 mm2 )	 participated	  participate	In 5 study sites	0.31	PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .
30240012	131 women aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 )	 participated	  participate	In 5 study sites	0.30	PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .
30240012	131 men	 aged	  age	18 to 85 years with a infection-prone skin lesion	0.24	PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .
30240021	tyrothricin 0.1 g tyrothricin per 100 g of vehicle	 was applied	  be apply	to the wound In a double-blind study twice daily for 9 days	0.31	In a double-blind study , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g of vehicle ) or placebo powder ( n = 69 ) was applied to the wound twice daily for 9 days .
30240021	placebo powder	 was applied	  be apply	to the wound In a double-blind study twice daily for 9 days	0.22	In a double-blind study , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g of vehicle ) or placebo powder ( n = 69 ) was applied to the wound twice daily for 9 days .
30240022	placebo powder	 was	  be	to be applied to the wound area 2 × daily During 9 days of double-blind treatment	0.83	During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily .
30240022	tyrothricin 0.1 g tyrothricin per 100 g base	 was	  be	to be applied to the wound area 2 × daily During 9 days of double-blind treatment	0.66	During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily .
30240022	tyrothricin 0.1 g tyrothricin per 100 g base	 to be applied	  to be apply	to the wound area 2 daily	0.41	During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily .
30240022	placebo powder	 to be applied ×	  to be apply ×	to the wound area 2 daily	0.11	During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily .
30240031	The primary aim	 was	  be	to evaluate the average daily reduction of the radius from the lesion area between the start and end of the randomized treatment (	0.83	The primary aim was to evaluate the average daily reduction of the radius from the lesion area between the start and end of the randomized treatment ( α = 0.025 ; one-sided ) .
30240032	The primary efficacy parameter	 was	  be	the average daily reduction in wound radius	0.95	The primary efficacy parameter was the average daily reduction in wound radius calculated from wound area between the start and end of randomized treatment ( α = 0.025 ; unilateral ) .
30240032	wound radius	 calculated	  calculate	from wound area between the start and end of randomized treatment ( α = 0.025	0.93	The primary efficacy parameter was the average daily reduction in wound radius calculated from wound area between the start and end of randomized treatment ( α = 0.025 ; unilateral ) .
30240041	a wound index	 was calculated	  be calculate	from the assessments of rubor	0.77	Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .
30240041	a wound index	 was calculated	  be calculate	from the assessments of crusting	0.19	Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .
30240041	a wound index	 was calculated	  be calculate	from the assessments of exudation	0.17	Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .
30240041	a wound index	 was calculated	  be calculate	from the assessments of pain	0.12	Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .
30240041	a wound index	 was calculated	  be calculate	from the assessments of functional impairment	0.03	Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .
30240042	A wound index	 was calculated	  be calculate	from the assessment of symptoms of redness	0.44	A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .
30240042	A wound index	 was calculated	  be calculate	from the assessment of symptoms of coatings	0.40	A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .
30240042	A wound index	 was calculated	  be calculate	from the assessment of symptoms of exudation	0.22	A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .
30240042	A wound index	 was calculated	  be calculate	from the assessment of symptoms of pain	0.13	A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .
30240042	A wound index	 was calculated	  be calculate	from the assessment of symptoms of functional limitation	0.10	A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .
30240051	The treatment groups	 were	  be	comparable at baseline	1.00	Results : The treatment groups were comparable at baseline .
30240052	Wound radius	 decreased	  decrease	by an average of 0.55 ± 0.31 mm/day ( mean ± s ) under tyrothricin and 0.47 ± 0.30 mm/day under placebo in the collective at comparable baseline intention-to-treat	0.34	Results : Wound radius decreased by an average of 0.55 ± 0.31 mm/day ( mean ± s ) under tyrothricin and 0.47 ± 0.30 mm/day under placebo in the intention-to-treat collective at comparable baseline ( p = 0.016 ; one-sided ) .
30240061	the radius of the lesions	 was reduced	  be reduce	at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for During randomized treatment	0.77	During randomized treatment , the radius of the lesions was reduced at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for placebo ( p = 0.016 ; one-sided ; intention-to-treat data set ) .
30240061	one-sided intention-to-treat data	 set	  set		0.48	During randomized treatment , the radius of the lesions was reduced at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for placebo ( p = 0.016 ; one-sided ; intention-to-treat data set ) .
30240062	The wound index	 decreased	  decrease	by a mean of 4.2 ± 1.7 points under tyrothricin and 3.3 ± 1.9 points under placebo	0.96	The wound index decreased by a mean of 4.2 ± 1.7 points under tyrothricin and 3.3 ± 1.9 points under placebo ( p = 0.0048 ; one-sided ) .
30240071	The wound index	 decreased respectively	  decrease respectively	at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin ,	0.47	The wound index decreased at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin and placebo , respectively ( p = 0.0048 ; one-sided ) .
30240071	The wound index	 decreased respectively	  decrease respectively	at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for placebo ,	0.36	The wound index decreased at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin and placebo , respectively ( p = 0.0048 ; one-sided ) .
30240072	a causal relationship with the medication	 could not be ruled out	  can not be rule out	in only 3 cases under placebo	1.00	Of 4 adverse events in each of the two treatment groups , a causal relationship with the medication could not be ruled out in only 3 cases under placebo .
30240081	4 adverse events	 occurred	  occur	in each group	1.00	4 adverse events occurred in each group .
30240082	The results	 demonstrate	  demonstrate	the promotion of healing of infection-prone skin lesions by Tyrothricin powder	0.68	Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .
30240082	The results	 demonstrate	  demonstrate	the promotion of healing of infected skin lesions by Tyrothricin powder	0.36	Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .
30240082	The results	 demonstrate	  demonstrate	its superiority over placebo	0.32	Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .
30240091	A causal relationship with the investigational drug	 could not be excluded	  can not be exclude	in 3 of the placebo group	1.00	A causal relationship with the investigational drug could not be excluded in 3 of the placebo group .
30240092	the substance	 is	  be	suitable for therapy in skin injuries	1.00	Due to the good tolerability and the lack of a systemic effect , the substance is suitable for therapy in skin injuries .
30240101	The results	 confirm	  confirm	the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection	0.67	Conclusion : The results confirm the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection or danger of infection .
30240101	The results	 confirm	  confirm	the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of danger of infection	0.65	Conclusion : The results confirm the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection or danger of infection .
30240111	A superior efficacy compared to placebo	 was demonstrated	  be demonstrate		0.98	A superior efficacy compared to placebo was demonstrated .
30240111	A superior efficacy	 compared	  compare	to placebo	0.91	A superior efficacy compared to placebo was demonstrated .
30240121	the absence of a systemic effects tyrothricin powder	 is	  be	appropriate for the treatment of superficial skin lesions	0.68	Due to its good tolerability and the absence of a systemic effects tyrothricin powder is appropriate for the treatment of superficial skin lesions .
30240121	tolerability tyrothricin powder	 is	  be	appropriate for the treatment of superficial skin lesions	0.11	Due to its good tolerability and the absence of a systemic effects tyrothricin powder is appropriate for the treatment of superficial skin lesions .
30250001	2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine	 reacted selectively	  react selectively	with aromatic amines by substitution at the 5-position	0.81	2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine ( 1 ) reacted with aromatic amines selectively by substitution at the 5-position to yield the amidines 2 .
30250002	2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine	 reacted selectively	  react selectively	with aromatic amines with substitution at the 5-position	0.96	2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine ( 1 ) reacted selectively with aromatic amines with substitution at the 5-position to give the amidines 2 .
30250011	The 4-aminophenol 2c	 could also be synthesized	  can also be synthesize	by cleavage of the ether 2b	1.00	The 4-aminophenol 2c could also be synthesized by cleavage of the ether 2b .
30250012	The 4-aminophenol 2c	 could also be prepared	  can also be prepare	by ether cleavage of 2b	1.00	The 4-aminophenol 2c could also be prepared by ether cleavage of 2b .
30250021	The structure of 2c	 was proved	  be prove	by X-ray crystal analysis	1.00	The structure of 2c was proved by X-ray crystal analysis .
30250031	Aminomethylation of 2c	 yielded	  yield	the amodiaquine analogue 3	1.00	Aminomethylation of 2c yielded the amodiaquine analogue 3 .
30250032	Aminomethylation of 2c	 afforded	  afford	the amodiaquine analogue 3	1.00	Aminomethylation of 2c afforded the amodiaquine analogue 3 .
30250041	The mono- derivatives 4	 were obtained	  be obtain	by reaction of compound 1 with phenol Mannich base hydrochlorides	0.48	The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .
30250041	The bisaminomethylated derivatives 4	 were obtained	  be obtain	by reaction of compound 1 with phenol Mannich base hydrochlorides	0.46	The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .
30250041	The bisaminomethylated derivatives 5	 were obtained	  be obtain	by reaction of compound 1 with phenol Mannich base hydrochlorides	0.28	The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .
30250041	The mono- derivatives 5	 were obtained	  be obtain	by reaction of compound 1 with phenol Mannich base hydrochlorides	0.27	The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .
30250042	Reaction of 1 with phenol Mannich base hydrochlorides	 gave	  give	the bisaminomethylated derivatives 4	0.53	Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .
30250042	Reaction of 1 with phenol Mannich base hydrochlorides	 gave	  give	the mono- derivatives 4	0.38	Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .
30250042	Reaction of 1 with phenol Mannich base hydrochlorides	 gave	  give	the bisaminomethylated derivatives 5	0.36	Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .
30250042	Reaction of 1 with phenol Mannich base hydrochlorides	 gave	  give	the mono- derivatives 5	0.25	Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .
30250051	Compounds 3–5	 were tested	  be test	in vitro for antimalarial activity	0.99	Compounds 3–5 were tested in vitro for antimalarial activity using chloroquine-sensitive and resistant Plasmodium-falciparum strains .
30250052	Compounds 3-5	 were tested	  be test	for activity against malaria with a chloroquine-sensitive Plasmodium falciparum strain in vitro	0.69	Compounds 3-5 were tested for activity against malaria with a chloroquine-sensitive and -resistant Plasmodium falciparum strain in vitro .
30250052	Compounds 3-5	 were tested	  be test	for activity against malaria with a -resistant Plasmodium falciparum strain in vitro	0.64	Compounds 3-5 were tested for activity against malaria with a chloroquine-sensitive and -resistant Plasmodium falciparum strain in vitro .
30250061	The highest activities	 were shown	  be show	by the pyronaridine-type compounds 5a with IC50	0.40	The highest activities were shown by the pyronaridine-type compounds 5a and 5b with IC50 values of approximately 200 nM .
30250061	The highest activities	 were shown	  be show	by the pyronaridine-type compounds 5b IC50	0.21	The highest activities were shown by the pyronaridine-type compounds 5a and 5b with IC50 values of approximately 200 nM .
30250062	Pyronaridine analogues 5a	 showed	  show	the best activities with IC50 values around 200 nM	0.87	Pyronaridine analogues 5a and 5b showed the best activities with IC50 values around 200 nM .
30250062	Pyronaridine analogues 5b	 showed	  show	the best activities with IC50 values around 200 nM	0.71	Pyronaridine analogues 5a and 5b showed the best activities with IC50 values around 200 nM .
